Researchers examined data from nearly 31,000 adult patients hospitalized with COVID-19, sharing their findings in Circulation: Arrhythmia and Electrophysiology.

New research, published in JAMA Cardiology, challenges the common belief that AFib is more likely to develop among men than women. The key problem, it seems, is that prior research teams did not understand the significance of certain risk factors.

The FDA granted the first pediatric indication for an implantable cardiac monitor. The Linq II can be used in pediatric patients over the age of 2 for up to 4.5 years of long-term, continuous monitoring. 

There is an established connection between MR and HFrEF, but we know much less about the link between MR and HFpEF. 

The FDA has approved a clinical trial to evaluate the safety and efficacy of a new type of ablation catheter for patients with ventricular tachycardia (VT) resistant to conventional anti-arrhythmic drugs or standard ablation procedures.

Affera’s portfolio includes interventional solutions such as the Affera Prism-1 mapping and navigation platform, designed to help electrophysiologists diagnose heart rhythm issues, and the Sphere-9 cardiac ablation catheter. 

ESC Congress 2022, the annual meeting of the European Society of Cardiology, was jam-packed with eye-opening new research from many of the leading voices in cardiovascular and vascular medicine. These six sessions were just some of the weekend's many highlights. 

Though removal of the affected CIED is typically the smartest treatment option—and one supported by specialty groups all over the world—a majority of patients keep living with the device, often resulting in hospitalization or even death.